Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.

Background: The ErbB family blocker, afatinib, is approved for patients with squamous cell carcinoma (SqCC) of the lung following platinum-doublet chemotherapy but has not been explored following immunochemotherapy. Here, we assessed the characteristics and outcomes of patients with SqCC of the lung who received second-line afatinib or chemotherapy after first-line pembrolizumab plus chemotherapy in a "real-world" setting.

Methods: In this retrospective, multisite cohort study, community oncologists identified eligible patients and extracted data from electronic health records.

Making the case for EGFR TKI sequencing in mutation-positive NSCLC: a GioTag study US patient analysis.

To assess time-to-treatment failure (TTF) in US patients with mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib-osimertinib treatment in the global, observational GioTag study. Patients had T790M mutation-positive disease after first-line afatinib and subsequently received osimertinib. The primary outcome was TTF.